Observational studyAnales del sistema sanitario de Navarra2026
[Achievement of pharmacokinetic/pharmacodynamic targets with linezolid therapeutic drug monitoring in critically ill patients].
Observational study in Anales del sistema sanitario de Navarra, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStandard dosing of linezolid regimen frequently results in suboptimal exposure in critically ill patients. This study aimed to analyze the association between dosing regimens (total daily dose and infusion duration) and the probability of achieving pharmacokinetic/pharmacodynamic targets, as well as their microbiological and clinical impact.
methodsA retrospective observational study was conducted in critically ill patients admitted to intensive care units who underwent therapeutic drug monitoring of linezolid between May 2021 and December 2023. Achievement of pharmacokinetic/pharmacodynamic targets (Cmin: 2-7 mg/L, AUC: 0-24/MIC: 80-120 mg*h/L, and T>MIC =85%) was evaluated according to the initial regimens (1,200 or 1,800 mg/day) and infusion duration (1 or 3 hours). Risk subgroups included obesity, augmented creatinine clearance, renal replacement therapy, and age <65 years.
resultsSeventy patients were included. At the first monitoring, only 18.6% achieved all three pharmacokinetic/pharmacodynamic targets and 40% achieved the Cmin target. No statistically significant differences were observed in target attainment according to dose or infusion duration, including within risk subgroups. However, the 1,800 mg/day regime showed a numerically higher proportion of patients achieving the Cmin target (54.5% vs. 37.3%). No significant differences in microbiological or clinical outcomes were observed between patients with Cmin within the target range and those outside it.
conclusionsFewer than 20% of critically ill patients achieve all pharmacokinetic/pharmacodynamic targets with the initial regimen. These findings support the need for individualized dosing and therapeutic drug monitoring to optimize linezolid treatment in this population, particularly in high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.